Company intelligence / Profile preview

Orbsen Therapeutics

Ownership
Private
Development stage
Other
01

Overview

Orbsen Therapeutics has reported encouraging interim results from the NEPHSTROM proof-of-concept clinical study evaluating its lead product, ORBCEL™, in patients with diabetes and advanced chronic kidney disease. The NEPHSTROM trial is a randomized, double-blind, placebo-controlled Phase 1/2a study showing safety, tolerability, and preliminary efficacy of this allogeneic stromal cell therapy. Additional programs are in earlier clinical or preclinical stages targeting other inflammatory and degenerative diseases[6].

Therapeutic areas
PulmonologyOphthalmologyGastroenterologyEndocrinologyNephrologyImmunology
Modalities
Cell therapyStromal cell therapyAllogeneic bone marrow-derived stromal cell therapy (ORBCEL™)
Industry
Biotech
02

Drug pipeline

2 assets

Orbcel-C

2

1 more asset in the full pipeline.

03

Partnerships

EU Horizon2020-funded consortia including multiple European academic medical centers [6]Collaborations with ~30 independent research laboratories across the EU [2]

Beyond the preview

Go deeper on Orbsen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orbsen Therapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call